DMPK Strategies for Oligonucleotide Therapeutics

Watch Now

Learn DMPK Strategies for Better Assessing Safety & Efficiency

The right DMPK testing strategy can significantly improve an oligonucleotide therapy’s success rate in translating a preclinical result to a clinical manifestation. In this on-demand webinar, WuXi AppTec’s Nan Zhao walks through the DMPK process for oligonucleotide therapeutics and how an effective study design can help move a project forward faster and more efficiently.

WuXi AppTec DMPK Services

WuXi AppTec is a global leader in preclinical drug development testing and world-class expert in DMPK & ADME. We are a full-service partner, acting as an extension of your team and providing end-to-end testing services and regulatory support.

Asset 1


DPMK Staff



Global Clients

Asset 1-1


In Vitro Studies per year